Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib.
Imatinib (Glivec or Gleevec) potently inhibits the tyrosine kinase activity of BCR-ABL, a constitutively activated kinase, which causes chronic myelogenous leukemia (CML). Here we report the first almost complete backbone assignment of c-ABL kinase domain in complex with imatinib.
Vajpai
Navratna
N
Biozentrum, University of Basel, Klingelbergstrasse 70, Basel, Switzerland.
Strauss
André
A
Fendrich
Gabriele
G
Cowan-Jacob
Sandra W
SW
Manley
Paul W
PW
Jahnke
Wolfgang
W
Grzesiek
Stephan
S
D000595:Amino Acid Sequence; D001549:Benzamides; D001665:Binding Sites; D002247:Carbon Isotopes / Q000737:chemistry; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D000068877:Imatinib Mesylate; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008969:Molecular Sequence Data; D008970:Molecular Weight; D009587:Nitrogen Isotopes / Q000737:chemistry; D010879:Piperazines / Q000737:chemistry*; D011485:Protein Binding; D047428:Protein Kinase Inhibitors / Q000737:chemistry; D011522:Protons; D011743:Pyrimidines / Q000737:chemistry*
D001549:Benzamides; D002247:Carbon Isotopes; D009587:Nitrogen Isotopes; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011522:Protons; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl